Skip to content

For Research & Educational Discussion Only. Not Medical Advice

Thymalin

Polypeptide fraction extracted from calf thymus

Also known as Thymus extract, Timalin

Not a defined molecule but a thymic extract, with a clinical literature that is almost entirely from one national research tradition and essentially no presence in the international trial registry.

Guide updated Sep 2, 2026Literature checked Sep 2, 20262 curated studies14 literature recordsBaseline editorial

This entry is preclinical

There is no completed human trial reporting results for this compound. Everything below describes what has been observed in animals or in cell culture, and the transfer rate from those findings to humans is poor. Read the limitations on each study, not just the findings.

Overview

In shortAn extract of calf thymus, developed in the Soviet Union and still used clinically in Russia and neighbouring states. It is not a single defined peptide, and that matters more here than anywhere else: what is in it depends on how it was extracted, so two products under the same name are not necessarily the same thing. Almost the whole literature comes from one research tradition.

Thymalin is a preparation of low-molecular-weight polypeptides extracted from calf thymus, developed in the Soviet Union and still used clinically in Russia and neighbouring states. It is not a single defined peptide, and that distinction matters more here than anywhere else in this compendium: the composition depends on the extraction, so two products under the same name are not necessarily the same thing.

There is a substantial literature, a few hundred papers, much of it reporting immunomodulatory and geroprotective effects. Almost all of it comes from a single research tradition, much of it is not in English, and the trial registry returns essentially nothing.

Mechanism

In shortThe proposal is that supplying thymus peptide signals restores immune function that declines with age, by influencing how immune cells mature. Because the preparation is a mixture rather than a single molecule, mechanism claims are harder to test than usual: attributing an effect to a specific peptide means isolating it, and the published work largely does not.

Proposed to restore thymic-dependent immune function by supplying thymic peptide signals, influencing T-lymphocyte differentiation and maturation.

Because the preparation is a mixture rather than a molecule, mechanism claims are harder to test than usual. Attributing an effect to a specific peptide requires isolating it, and the published work largely does not.

Evidence

In shortDifficult to assess honestly, and that is a finding rather than a hedge. Clinical reports exist, including long-running studies of elderly groups claiming effects on illness and survival. They come almost exclusively from one group in one country and have not been independently replicated. The usual ways of checking them have not been applied.

Difficult to assess honestly, and this entry is a good example of why that is a finding rather than a hedge.

Clinical reports exist, including long-running studies of elderly cohorts claiming effects on morbidity and survival. They come almost exclusively from one group of researchers in one country, are frequently published in journals that are hard to access or evaluate from outside, and have not been replicated independently.

That is not evidence that the claims are wrong. It is a statement that the usual mechanisms for checking them have not been applied. Anyone citing the survival findings should say where they come from.

Safety

In shortReported as well tolerated in the Russian clinical literature at the doses used there. The specific risk here is not unusual toxicity, it is the preparation itself: an extract of animal tissue carries immune-reaction and contamination considerations a synthetic peptide does not, and those depend on manufacturing standards that cannot be verified from outside.

Reported as well tolerated in the Russian clinical literature, at the doses and durations used there.

The specific risk here is not idiosyncratic toxicity, it is the preparation itself. An extract of animal tissue carries immunogenicity and contamination considerations that a synthetic peptide does not, and those depend entirely on manufacturing standards that are not verifiable from outside for grey-market product.

Regulatory status

In shortRegistered as a medicine in Russia and some neighbouring states. Not approved in the US, the EU, the UK or Australia. Because the product is defined by how it is extracted rather than by its structure, a buyer has no straightforward way to confirm it is the same preparation the literature describes.

Registered as a medicine in Russia and some neighbouring states. Not approved in the United States, the European Union, the United Kingdom or Australia.

Material sold internationally under this name is research-use-only, and given that the product is defined by its extraction rather than its structure, there is no straightforward way for a buyer to confirm it is the same preparation the literature describes.

The literature

2 studies indexed. Findings and limitations get equal weight, on purpose.

Always check the primary source

Members area

The Thymalin literature needs an account

Everything above is free to read. What an account opens is the evidence underneath it: 2 studies with their limitations, and the regimen each trial actually reported.

  • Every study, with what it found and what it cannot show
  • The limitations, given the same weight as the findings
  • The dose each named trial administered, where recorded

Free to create. A membership is separate, and you can decide about that later.

Reading is free, an account is not the same as paying. 43 compound guides, every study with its limitations written underneath, and the regimens those trials actually used. A free account opens all of it. A membership is a separate decision, and it opens the forum. What membership costs.

The wider literature

14 indexed papers and 0 registered trials mentioning Thymalin, straight from PubMed and ClinicalTrials.gov. These have not been read by us. Unlike the studies above, they carry no findings and no limitations written by anyone here, because writing either would mean claiming a reading nobody has done. They are a starting point for yours.

Papers (14)

  1. Oral Supplementation With a Bovine Thymus Extract Reduces Neuronal Excitability in Aging Mice.

    El-Idrissi A, et al.FASEB bioAdvances2026PMID 41624337

    journal article

  2. Immunoregulatory actions of calf thymus extract (TFX®) in vitro in relation to its effect on expression of mitogen activated protein kinases.

    Zimecki M, et al.International immunopharmacology2023PMID 36963263

    journal article

  3. Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line.

    Avolio F, et al.International journal of molecular sciences2022PMID 35408963

    journal article

  4. Effectiveness and Safety of A Nutraceutical Formulation for the Treatment of Functional Dyspepsia in Primary Care.

    Tursi A, et al.Reviews on recent clinical trials2021PMID 34126909

    journal article

  5. [Sensitivity of patients to immunomodulators in immunodeficiency diseases].

    Stasenko AA, et al.Klinichna khirurhiia2014PMID 25417290

    english abstractjournal article

  6. [Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results].

    Khavinson VKh, et al.Advances in gerontology = Uspekhi gerontologii2013PMID 24003726

    english abstractjournal articlereview

  7. [The use of Timalin in the treatment of the acute lung abscess].

    Tsybikov MN, et al.Khirurgiia2012PMID 23258355

    english abstractjournal article

  8. Calf thymus extract attenuates severity of experimental encephalomyelitis in Lewis rats.

    Zimecki M, et al.Folia neuropathologica2010PMID 21225507

    journal articleresearch support, non-u.s. gov't

  9. [Geroprotective effect of thymalin and epithalamin].

    Khavinson VKh, et al.Advances in gerontology = Uspekhi gerontologii2002PMID 12577695

    english abstractjournal articlereview

  10. Interactions between zinc and thymulin.

    Dardenne M, et al.Metal-based drugs1994PMID 18476235

    journal article

  11. Therapeutic application of calf thymus extract (TFX).

    Skotnicki ABMedical oncology and tumor pharmacotherapy1989PMID 2657248

    journal articlereview

  12. Indications for immunotherapy.

    Solinger AMPharmacotherapy1987PMID 3299294

    journal articlereview

  13. [Correction of the T immunological system deficit in experimental and clinical tuberculosis].

    Alexandrova AE, et al.Revista de igiena, bacteriologie, virusologie, parazitologie, epidemiologie, pneumoftiziologie. Pneumoftiziologia1981PMID 6264576

    english abstractjournal article

  14. Lymphocyte-differentiating hormone of bursa of fabricius.

    Brand A, et al.Science (New York, N.Y.)1976PMID 180600

    journal articleresearch support, u.s. gov't, p.h.s.

Discussion

Thymalin has its own forum, split by the same six categories as the rest of the site.

1976 to 2026: Thymalin has had 50 years and no trial

The oldest record the importer found for Thymalin is from 1976. The newest is 2026. That is…

Members only. Join to read the rest

@baselineAdmin000

Membership

Peptides is free. The argument is for members.

The guide above is open to everyone, and the literature underneath it opens with a free account. That is the educational half of this site. Reading and joining the discussion around Thymalin, and every other entry, is what membership pays for.

Unlock membershipSign in

From $3.33 a month, billed annually. Cancel anytime.

For Research & Educational Discussion Only. Not Medical Advice

This guide is educational reference material compiled from published literature. It is not medical advice, not a recommendation, and not a substitute for a clinician who knows your history. Nothing here should be used to make a decision about your own health without one.

Talk to a licensed healthcare professional.